EP1732518A1 - Clarithromycin extended release formulation - Google Patents

Clarithromycin extended release formulation

Info

Publication number
EP1732518A1
EP1732518A1 EP05764065A EP05764065A EP1732518A1 EP 1732518 A1 EP1732518 A1 EP 1732518A1 EP 05764065 A EP05764065 A EP 05764065A EP 05764065 A EP05764065 A EP 05764065A EP 1732518 A1 EP1732518 A1 EP 1732518A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
extended release
pharmaceutically acceptable
composition according
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05764065A
Other languages
German (de)
French (fr)
Inventor
Suryakumar Lupin Limited -Research Park JAYANTHI
Vineeth Lupin Limited -Research Park RAGHAVAN
Nilesh Lupin Limited -Research Park BHANDARI
Himadri Lupin Limited -Research Park SEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of EP1732518A1 publication Critical patent/EP1732518A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to extended release pharmaceutical compositions of erythromycin or derivatives thereof for once daily administration.
  • Erythromycin and derivatives are known for their anti-bacterial activity against a number of micro-organisms and are typically administered as immediate release (IR) compositions, two or three times a day, for a regimen of 10 to 14 days.
  • IR immediate release
  • 6-O-methylerythromycin A (Clarithromycin), which has been disclosed in US patent No. 4,331,803. It is currently marketed by Abbott as an immediate release formulation, for at least twice daily administration. Abbott is also marketing controlled release composition of Clarithromycin 500 mg under the brand "Biaxin XL".
  • Literature discloses various approaches for therapeutic dosage forms, which are designed to deliver the drug at an extended rate to the gastrointestinal tract.
  • U.S. Patent 4,842,866 discloses the development of a controlled release formulation of erythromycin derivatives using an alginate matrix comprising a water-soluble alginate and a complex salt of alginic acid, having one cation that yields a soluble alginate salt and another cation that alone yields an insoluble alginate salt.
  • US patents 6,010,718, and 6,551,616 disclose formulations of extended release clarithromycin containing 5 to 50% w/w of pharmaceutically acceptable polymer.
  • the specification and examples of this patent disclose preferred formulations containing 10%-
  • US patent application 2003/0175341 discloses controlled release formulations containing about 0.1% to about 4.5% of one or more cellulosic ether rate controlling polymers.
  • PCT application WO 03/082241 discloses clarithromycin formulations having improved bioavailability, using micronized drug.
  • the patent exemplifies formulations of extended release clarithromycin containing the drug of particle size less than 35 microns. Improved dissolution relative to un-micronized drug is documented in the said patent. However, the formulation as disclosed in the patent application does not show significant improvement in bioavailability.
  • U.S. Pat. No. 4,389,393 describes sustained release therapeutic composition using less than about one third of the weight of the solid unit dosage form, of hydroxypropyl methylcellulose or a mixture of hydroxypropyl methylcellulose with certain other rate controlling polymers.
  • the inventors disclose that they have been able to achieve sustained release from solid dosage forms containing as little as about 5 to about 30 weight percent of these hydroxypropyl methylcelluloses. All the examples disclose compositions containing 9% or more of the rate-controlling polymer.
  • compositions prepared using polymers in the range of about 50% to about 65% showed pharmacokinetic profile similar to the innovator, which has lower polymer content.
  • the object of the present invention is to provide a pharmaceutical composition for extended release of erythromycin or its derivatives for once daily administration comprising about 50% to about 65% by weight of pharmaceutically acceptable polymers.
  • Another object of the invention is to provide a process for preparing extended release composition of erythromycin or its derivatives comprising mixing the drug with about 50% to about 65% by weight of one or more than one of pharmaceutically acceptable polymers, granulating the blend by wet or dry means, followed by either filling the granules into capsules, sachets or compressing them into tablets.
  • Yet another object of the present invention is to provide a pharmaceutical composition for extended release of Clarithromycin comprising from about 50% to about 65% of pharmaceutically acceptable polymers, wherein the T/R ratio of the geometric mean of Cmax and AUC are within acceptable limit (80-125%) with respect to the currently marketed extended release Clarithromycin formulation marketed under the trade name Biaxin XL.
  • an extended release formulation of erythromycin or its derivatives suitable for once daily oral administration comprising about 50% to about 65% by weight of pharmaceutically acceptable polymers or combinations thereof.
  • the invention provides for an extended release formulation of erythromycin or derivatives thereof, comprising erythromycin or derivatives thereof, pharmaceutically acceptable polymers in the range of about 50% to about 65% by weight, in addition to other pharmaceutically acceptable excipients
  • the extended release formulation of the invention is prepared by following the processes of wet or dry granulation, filling the granules into capsules, sachets or compressing into tablets.
  • Erythromycin or derivatives used according to the present invention comprise about 10% to about 40% of the total weight of the formulation.
  • the pharmaceutically acceptable polymers are present in the range of about 50% to about 65% by weight.
  • the pharmaceutically acceptable polymers according to the present invention may be selected from group of polyvinyl pyrrolidine, celluloses, polyvinyl pyrrolidone/polyvinyl acetate copolymers, polyethylene oxide polymers, acrylic acid polymers, methacrylic acid copolymers, natural gums, and derivatives and mixtures thereof.
  • Celluloses used in accordance with the present invention include hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, methylcellulose and the like.
  • the viscosity of the polymers may be in the range of 5 to 200 cps.
  • Polyvinyl pyrrolidone/polyvinyl acetate copolymers according to the present invention may be such as available under the brand name Kollidon SR (BASF).
  • Polyethylene oxide polymers are sold by Union Carbide.
  • Acrylic acid polymers according to the present invention may be such as available under the brand name carbopol (B.F. Goodrich, USA).
  • composition may contain pharmaceutically acceptable excipients such as buffering agents, binders, lubricants and fillers.
  • Fillers according to the present invention may be selected from amongst those conventionally used in the art such as lactose, starches, glucose, sucrose, mannitol, silicic acid and mixtures thereof.
  • composition according to the present invention may also contain pharmaceutically acceptable lubricants such as those selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycol, silicon dioxide, sodium stearyl fumarate and the like.
  • pharmaceutically acceptable lubricants such as those selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycol, silicon dioxide, sodium stearyl fumarate and the like.
  • the release profile of the product is evaluated using USP apparatus Type 1 (basket), at 100 rpm in 900 ml. Medium for 0 to 2h, pH 3.5 acetate buffer. The medium was then changed to pH 6.8 phosphate buffer, for the next 12 hours.
  • Example 1 i) Clarithromycin 38.46 % ii) Hydroxypropyl Methylcellulose lOOcps 7.00 % iii) Hydroxypropyl Methylcellulose 5cps 48.00 % iv) Lactose 4.23 % v) Talc 1.54 % vi) Magnesium Stearate 0.77 % vii) Water qs
  • Example 3 i) Clarithromycin 38.46 % ii)Hydroxypropyl Methylcellulose 5cps 46.50 % iii) Hydroxypropyl Methylcellulose lOOcps 7.00 % iv) Sodium alginate (Keltone LVCR) 1.50 % v) Lactose 4.23 % vi) Talc 1.54 % vii) Magnesium Stearate 0.77 % viii) Water qs
  • Example 4 i) Clarithromycin 38.46 % ii) Hydroxypropyl Methylcellulose lOOcps 10.00 % iii) Hydroxypropyl Methylcellulose 5cps 45.00 % iv) Lactose 4.23 % v) Talc 1.54 % vi) Magnesium Stearate 0.77 % vii) Water qs
  • Example 6 i) Clarithromycin 35.89 % ii)Hydroxypropyl Methylcellulose 5cps 48.50 % iii) Hydroxypropyl Methylcellulose lOOcps 7.00 % ( Methocel KlOO LN) iv) Sodium alginate (Keltone LNCR) 1.50 % v) Xanthan Gum 1.00 % vi) Lactose 3.95 % vii) Talc 1.44 % viii) Magnesium Stearate 0.72 % ix) Water qs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition for extended release of erythromycin or a derivative thereof. the composition comprises comprising a pharmaceutically effective amount of the drug and about 50% to about 65% by weight of one or more pharmaceutically acceptable polymer(s). The pharmaceutically acceptable polymer(s) are selected from the group comprising polyvinyl pyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, ethyl cellulose, polyvinyl pyrrolidone/polyvinyl acetate copolymers, polyethylene oxide polymers, acrylic acid polymers, methacrylic acid copolymers, natural gums, and derivatives and mixtures thereof.

Description

CLARITHROMYCIN EXTENDED RELEASE FORMULATION
FIELD OF INVENTION
The present invention relates to extended release pharmaceutical compositions of erythromycin or derivatives thereof for once daily administration.
BACKGROUND OF THE INVENTION
The advantages of extended release dosage forms are well known i.e. reduced daily dosage, patient convenience and improved patient compliance. Erythromycin and derivatives are known for their anti-bacterial activity against a number of micro-organisms and are typically administered as immediate release (IR) compositions, two or three times a day, for a regimen of 10 to 14 days.
In particular the 6-O-methylerythromycin A (Clarithromycin), which has been disclosed in US patent No. 4,331,803. It is currently marketed by Abbott as an immediate release formulation, for at least twice daily administration. Abbott is also marketing controlled release composition of Clarithromycin 500 mg under the brand "Biaxin XL".
Literature discloses various approaches for therapeutic dosage forms, which are designed to deliver the drug at an extended rate to the gastrointestinal tract.
U.S. Patent 4,842,866 discloses the development of a controlled release formulation of erythromycin derivatives using an alginate matrix comprising a water-soluble alginate and a complex salt of alginic acid, having one cation that yields a soluble alginate salt and another cation that alone yields an insoluble alginate salt.
U.S. Patent 5,705,190, claims formulations using soluble alginate, a complex salt of alginic acid and an organic carboxylic acid. The said patent discloses compositions containing equimolar quantities of citric acid and clarithromycin.
US patents 6,010,718, and 6,551,616 disclose formulations of extended release clarithromycin containing 5 to 50% w/w of pharmaceutically acceptable polymer. The specification and examples of this patent disclose preferred formulations containing 10%-
30% by weight of hydroxypropyl methylcellulose, the rate-controlling polymer, in the formulation in addition to other excipients. This patent covers Clarithromycin extended release formulation currently marketed under the trade name Biaxin XL™.
US patent application 2003/0175341 discloses controlled release formulations containing about 0.1% to about 4.5% of one or more cellulosic ether rate controlling polymers.
PCT application WO 03/082241 discloses clarithromycin formulations having improved bioavailability, using micronized drug. The patent exemplifies formulations of extended release clarithromycin containing the drug of particle size less than 35 microns. Improved dissolution relative to un-micronized drug is documented in the said patent. However, the formulation as disclosed in the patent application does not show significant improvement in bioavailability.
U.S. Pat. No. 4,389,393 describes sustained release therapeutic composition using less than about one third of the weight of the solid unit dosage form, of hydroxypropyl methylcellulose or a mixture of hydroxypropyl methylcellulose with certain other rate controlling polymers. In the specification of this patent, the inventors disclose that they have been able to achieve sustained release from solid dosage forms containing as little as about 5 to about 30 weight percent of these hydroxypropyl methylcelluloses. All the examples disclose compositions containing 9% or more of the rate-controlling polymer.
It has been surprisingly found that compositions prepared using polymers in the range of about 50% to about 65% showed pharmacokinetic profile similar to the innovator, which has lower polymer content.
OBJECT OF THE INVENTION
The object of the present invention is to provide a pharmaceutical composition for extended release of erythromycin or its derivatives for once daily administration comprising about 50% to about 65% by weight of pharmaceutically acceptable polymers.
Another object of the invention is to provide a process for preparing extended release composition of erythromycin or its derivatives comprising mixing the drug with about 50% to about 65% by weight of one or more than one of pharmaceutically acceptable polymers, granulating the blend by wet or dry means, followed by either filling the granules into capsules, sachets or compressing them into tablets.
Yet another object of the present invention is to provide a pharmaceutical composition for extended release of Clarithromycin comprising from about 50% to about 65% of pharmaceutically acceptable polymers, wherein the T/R ratio of the geometric mean of Cmax and AUC are within acceptable limit (80-125%) with respect to the currently marketed extended release Clarithromycin formulation marketed under the trade name Biaxin XL.
SUMMARY OF THE INVENTION
According to a basic aspect of the present invention there is provided an extended release formulation of erythromycin or its derivatives suitable for once daily oral administration, comprising about 50% to about 65% by weight of pharmaceutically acceptable polymers or combinations thereof.
According to a preferred aspect the invention provides for an extended release formulation of erythromycin or derivatives thereof, comprising erythromycin or derivatives thereof, pharmaceutically acceptable polymers in the range of about 50% to about 65% by weight, in addition to other pharmaceutically acceptable excipients
The extended release formulation of the invention is prepared by following the processes of wet or dry granulation, filling the granules into capsules, sachets or compressing into tablets.
DETAILED DESCRIPTION OF THE INVENTION
Erythromycin or derivatives used according to the present invention comprise about 10% to about 40% of the total weight of the formulation. The pharmaceutically acceptable polymers are present in the range of about 50% to about 65% by weight.
The pharmaceutically acceptable polymers according to the present invention may be selected from group of polyvinyl pyrrolidine, celluloses, polyvinyl pyrrolidone/polyvinyl acetate copolymers, polyethylene oxide polymers, acrylic acid polymers, methacrylic acid copolymers, natural gums, and derivatives and mixtures thereof.
Celluloses used in accordance with the present invention include hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, methylcellulose and the like. The viscosity of the polymers may be in the range of 5 to 200 cps.
Polyvinyl pyrrolidone/polyvinyl acetate copolymers according to the present invention may be such as available under the brand name Kollidon SR (BASF).
Polyethylene oxide polymers are sold by Union Carbide.
Natural gums according to the present invention include Xanthan gum, Locust bean gum, guar gum, gum karaya, alginates and the like.
Acrylic acid polymers according to the present invention may be such as available under the brand name carbopol (B.F. Goodrich, USA).
In addition to the pharmaceutically acceptable polymers the composition may contain pharmaceutically acceptable excipients such as buffering agents, binders, lubricants and fillers.
Buffering agents may be selected from the groups comprising alkali and alkaline earth metal phosphates, citrates, succinates, and the like.
Fillers according to the present invention may be selected from amongst those conventionally used in the art such as lactose, starches, glucose, sucrose, mannitol, silicic acid and mixtures thereof.
The composition according to the present invention may also contain pharmaceutically acceptable lubricants such as those selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycol, silicon dioxide, sodium stearyl fumarate and the like.
The release profile of the product is evaluated using USP apparatus Type 1 (basket), at 100 rpm in 900 ml. Medium for 0 to 2h, pH 3.5 acetate buffer. The medium was then changed to pH 6.8 phosphate buffer, for the next 12 hours.
EXAMPLES
The following examples illustrate the invention, without limiting it.
Example 1 i) Clarithromycin 38.46 % ii) Hydroxypropyl Methylcellulose lOOcps 7.00 % iii) Hydroxypropyl Methylcellulose 5cps 48.00 % iv) Lactose 4.23 % v) Talc 1.54 % vi) Magnesium Stearate 0.77 % vii) Water qs
Procedure: The drug and excipients were blended and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness.
Example 2 i) Clarithromycin 38.46 % ii) Hydroxypropyl Methylcellulose 5cps 50.00 % iii) Kollidone SR 5.00 % iv) Lactose 4,23 % v) Talc 1.54 % vi) Magnesium Stearate 0.77 % vii) Water qs Procedure : The drug and excipients were blended and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness.
Example 3 i) Clarithromycin 38.46 % ii)Hydroxypropyl Methylcellulose 5cps 46.50 % iii) Hydroxypropyl Methylcellulose lOOcps 7.00 % iv) Sodium alginate (Keltone LVCR) 1.50 % v) Lactose 4.23 % vi) Talc 1.54 % vii) Magnesium Stearate 0.77 % viii) Water qs
Procedure: The drug and excipients were blended and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness.
Example 4 i) Clarithromycin 38.46 % ii) Hydroxypropyl Methylcellulose lOOcps 10.00 % iii) Hydroxypropyl Methylcellulose 5cps 45.00 % iv) Lactose 4.23 % v) Talc 1.54 % vi) Magnesium Stearate 0.77 % vii) Water qs
Procedure: The drug and excipients were blended, and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness. ample 5 i) Clarithromycin 35.89 % ii)Hydroxypropyl Methylcellulose 5cps 48.00 % iii) Hydroxypropyl Methylcellulose lOOcps 7.00 % (Methocel KlOO LN) iv) Sodium alginate (Keltone LNCR) 3.00 % v) Lactose 3.95 % vi) Talc 1.44 % vii) Magnesium Stearate 0.72 % viii) Water qs
Procedure: The drug and excipients were blended and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness.
Example 6 i) Clarithromycin 35.89 % ii)Hydroxypropyl Methylcellulose 5cps 48.50 % iii) Hydroxypropyl Methylcellulose lOOcps 7.00 % ( Methocel KlOO LN) iv) Sodium alginate (Keltone LNCR) 1.50 % v) Xanthan Gum 1.00 % vi) Lactose 3.95 % vii) Talc 1.44 % viii) Magnesium Stearate 0.72 % ix) Water qs
Procedure: The drug and excipients were blended and granulated with water. The granules were dried, sized, lubricated and compressed into tablets of suitable size and hardness. Dissolution profiles of the above examples are summarized below in Table I:
Formulation prepared according to one of the preceeding examples was subjected to a bioequivalence study against the extended release formulation of Clarithromycin marketed under the name Biaxin XL TM in the US. The T/R ratio of geometric mean of Cmax and AUC was within acceptable limits (80%-125%) as shown in Table II.
It was surprisingly found that our formulation comprising from about 50% to about 65% of pharmaceutically acceptable polymers was bio-equivalent to Biaxin XL.

Claims

1. A pharmaceutical composition for extended release of erythromycin or a derivative thereof, comprising a pharmaceutically effective amount of the drug and about 50% to about 65% by weight of one or more pharmaceutically acceptable polymer(s).
2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable polymer(s) are selected from the group comprising polyvinyl pyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, ethyl cellulose, polyvinyl pyrrolidone/polyvinyl acetate copolymers, polyethylene oxide polymers, acrylic acid polymers, methacrylic acid copolymers, natural gums, and derivatives and mixtures thereof.
3. The extended release pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable polymer(s) is hydroxypropylmethyl cellulose or combinations thereof.
4. The extended release pharmaceutical composition according to claim 3, wherein the hydroxypropylmethyl cellulose with viscosity ranging from about 5 to about 200 cps.
5. The extended release pharmaceutical composition according to claim 1, wherein the composition comprises from about 30% to about 45% by weight of the erythromycin or a derivative.
6. The extended release pharmaceutical composition according to claim 1 , wherein the erythromycin derivative is clarithromycin.
7. A pharmaceutical composition prepared according to claim 1, wherein the extended release composition further comprises pharmaceutical aids such as buffering agents, fillers, binders and lubricants.
8. A pharmaceutical composition according to claim 7, wherein the buffering agents may be selected from the groups comprising alkali and alkaline earth metal phosphates, citrates, succinates, and the like.
9. A pharmaceutical composition according to claim 7, wherein the fillers may be selected from lactose, starch, glucose, sucrose, mannitol, silicic acid and mixtures thereof.
10. A pharmaceutical composition according to claim 7, wherein the binder is selected from starch, polyvinyl pyrrolidone, gelatin, gums and the like.
11. A pharmaceutical composition according to claim 7 wherein the lubricants are selected from talc, stearates, polyethylene glycol, silicon dioxide, sodium stearyl fumarate and the like.
12. A method of using an extended release composition comprising erythromycin or its derivatives and about 50% to about 65% by weight of pharmaceutically acceptable polymer(s), for the treatment of bacterial infections in a mammal.
13. A process for preparing extended release composition of erythromycin or its derivatives, comprising mixing the drug with about 50% to about 65% by weight of one or more than one of pharmaceutically acceptable polymers, granulating the blend by wet or dry means, followed by either filling the granules into capsules or sachets or compressing them into tablets.
14. A pharmaceutical composition for extended release according to claim 1, wherein the T/R ratio of geometric means of C max and AUC are within the acceptable limits(80% - 125%) in comparison with Clarithromycin controlled release formulation as shown in Table II.
EP05764065A 2004-03-24 2005-03-17 Clarithromycin extended release formulation Withdrawn EP1732518A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN356MU2004 2004-03-24
PCT/IN2005/000085 WO2005102289A1 (en) 2004-03-24 2005-03-17 Clarithromycin extended release formulation

Publications (1)

Publication Number Publication Date
EP1732518A1 true EP1732518A1 (en) 2006-12-20

Family

ID=34979410

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05764065A Withdrawn EP1732518A1 (en) 2004-03-24 2005-03-17 Clarithromycin extended release formulation

Country Status (5)

Country Link
EP (1) EP1732518A1 (en)
AU (1) AU2005235237A1 (en)
BR (1) BRPI0508743A (en)
MX (1) MXPA06010805A (en)
WO (1) WO2005102289A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476403B2 (en) * 2003-06-16 2009-01-13 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2007123021A1 (en) * 2006-04-12 2007-11-01 Nippon Soda Co., Ltd. Method for producing extended release tablet
WO2008114143A1 (en) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Extended release formulations of macrolide antibiotic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20150A (en) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Directly compressible matrix for controlled release of the daily dose of clarytomicyne
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US7476403B2 (en) * 2003-06-16 2009-01-13 Andrx Pharmaceuticals, Llc Oral extended-release composition
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005102289A1 *

Also Published As

Publication number Publication date
WO2005102289A1 (en) 2005-11-03
BRPI0508743A (en) 2008-01-22
MXPA06010805A (en) 2006-12-19
AU2005235237A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
AU628754B2 (en) Therapeutic agents
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
CN106943355B (en) Pharmaceutical composition
JPH11505542A (en) Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing
US20070059365A1 (en) Novel formulation of ropinirole
WO2004019901A2 (en) Sustained release pharmaceutical composition
WO2019073477A1 (en) Extended release pharmaceutical composition of apremilast
US7943585B2 (en) Extended release antibiotic composition
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
WO2005020998A1 (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation
US20110086102A1 (en) Delayed release compositions
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2005102289A1 (en) Clarithromycin extended release formulation
US20060233878A1 (en) Extended release formulation of beta-lactam antibiotics
WO2003011256A1 (en) Oral controlled release pharmaceutical composition of a prokinetic agent
CA2458776A1 (en) Controlled release formulation of clarithromycin or tinidazol
WO2005082331A2 (en) Extended release tablets of clarithromycin
WO2005067895A1 (en) Controlled release pharmaceutical compositions
US20040096496A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
JPWO2013147135A1 (en) Controlled release pharmaceutical composition
JP2009525953A (en) Sustained release formulation of divalproic acid and its derivatives
US20110287091A1 (en) Chronotherapeutic pharmaceutical composition
WO2023044024A1 (en) Novel ph dependent coating drug delivery system
WO2022157357A1 (en) Prolonged-release furazidin composition
EP2488173A1 (en) Delayed release compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR MK

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20061016

Extension state: HR

Payment date: 20061016

17Q First examination report despatched

Effective date: 20100415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151001